
1. j antimicrob chemother. 2013 apr;68(4):786-8. doi: 10.1093/jac/dks471. epub 2012 
nov 20.

antimalarial activity isoquine kenyan plasmodium falciparum clinical
isolates association polymorphisms pfcrt pfmdr1 genes.

okombo j(1), kiara sm, abdirahman a, mwai l, ohuma e, borrmann s, nzila a, ward
s.

author information: 
(1)kenya medical research institute (kemri)/wellcome trust collaborative research
program, po box 230, 80108 kilifi, kenya. jokombo@kemri-wellcome.org

background: use amodiaquine prophylaxis associated serious
toxicity, resulting metabolic conversion reactive quinone-imine
metabolite hepatic cytochrome p450. circumvent toxicity, several
amodiaquine analogues lack potential form quinone-imine derivative,
while retaining antimalarial activity, designed. isoquine one of
these promising molecules already reached phase clinical trials in
humans.
methods: analysed vitro activity isoquine 62 plasmodium
falciparum isolates collected kenya association activity 
polymorphisms pfcrt pfmdr1 genes.
results: median concentration isoquine inhibited 50% parasite
growth (ic50) 9 nm, compared 56 nm chloroquine, 8 nm amodiaquine, 10 nm 
desethylamodiaquine, 69 nm lumefantrine 1 nm dihydroartemisinin. isoquine
activity correlated polymorphisms pfcrt codon 76, in
pfmdr1 codon 86.
conclusions: high activity isoquine field isolates, including
chloroquine-resistant isolates, ic50 <10 nm, warrants further
development antimalarial.

doi: 10.1093/jac/dks471 
pmid: 23169890  [indexed medline]

